Corcept Therapeutics

Chief Executive Officer

David B......

Mr. is responsible for Maverick's Private Investments globally. He joined Maverick in 2004 from Oscient Pharmaceutical Corporation, where he was Chairman of the Board.

Mr. is a founder and former CEO of three healthcare companies: Affymetrix, Inc., Corcept Therapeutics, Inc., and Genesoft Pharmaceuticals, Oscient's predecessor. Mr. currently serves on the boards of several private companies.

Mr. received a B......A. from Yale University and an M.B......A. from Stanford University.

He was a Crown Fellow of the Aspen Institute, and is currently a Sterling Fellow of Yale University, a member of the Rand Corporation's Health Advisory Board and a director of College Track.

Chief Executive Officer

Joe B......

Director

Patrick E......

Patrick E...... is the Board Member at Esperion Therapeutics.
He has served as a Member Of Board Of Directors since April 2013.

He is also the Managing Director, Longitude Capital Management Co., LLC. Patrick is a founder of Longitude Capital Management Co., LLC, a venture capital firm focused on investments in biotechnology, and has served as its Managing Director since 2007.

From 2002 through 2006, Patrick was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice.

Prior to Pequot, Patrick was a Managing Member responsible for the Delta Opportunity Fund, where he invested in privately held and publicly traded biotechnology companies.

Patrick is a director of a number of companies including,

Corcept Therapeutics, Inc. (NASDAQ: CORT),

Jazz Pharmaceuticals plc (NASDAQ: JAZZ).

Patrick earned an M.B.A. from the Wharton School of Business at the University of Pennsylvania.

B.S.

Director

David M......

David M...... was appointed to Symantec's board of directors in April 2003. He previously served as co-CEO of McKesson HBOC, Inc. and as CEO of iMcKesson LLC from July 1999 to February 2001. M...... joined McKesson in 1990 as vice president for Strategic Planning, and was responsible for planning and corporate development.

He had overall responsibility for McKesson's strategic relations with pharmaceutical and biotechnology companies, was responsible for the establishment of the Pharmaceutical Partners Group at McKesson, and the launch of a new generics program.

Prior to joining McKesson, M...... was a principal with McKinsey & Company from 1981 to 1990. He serves on the board of directors of Adamas Pharmaceuticals, Corcept Therapeutics, Inc., Schwab Funds/Loudus Funds, SFMOMA, and Mercy Corps.

He has a bachelor's degree from Princeton University and a master's of business administration from Harvard University.

Director

Joseph T......

Joseph L. T...... has served as a member of our Board since January 2008. Mr. T...... retired from active employment in 2006 and currently serves on the board of directors of several companies.

From 1999 to 2006, Mr. T...... served as the Chief Financial Officer at Myogen, Inc., a pharmaceutical company, where he led several rounds of financing and was pivotal in the negotiation of the sale of the company.

Mr. T...... has also served in other finance roles including Director of Finance, Eli Lilly and Company, a biopharmaceutical company, (Switzerland) and Treasurer, Eli Lilly and Company (Switzerland).

He serves on the boards of four pharmaceutical companies: Alexza Pharmaceuticals, Inc., Corcept Therapeutics, Inc., BioClin Therapeutics, Inc. and Sophiris Bio Inc. Previously, he has served on the boards of NovaCardia, Inc., Sequel Pharmaceuticals, ApoLogic Inc., SGX Pharmaceuticals, Allos Therapeutics, Inc, and QLT Inc.

Mr. T...... received a B.A.